Disproportionality analysis of the European Pharmacovigilance database found no elevated signal for suicidal events with GLP-1 receptor agonists as a class.
No elevated signalAmong 230 reports of suicidal events with GLP-1 drugs over 5.5 years, disproportionality analysis found no class-wide safety signal
What the researchers found
Disproportionality analysis of the European Pharmacovigilance database found no elevated signal for suicidal events with GLP-1 receptor agonists as a class.
Why it matters
Millions of people take GLP-1 drugs, and a possible suicide link would be a major safety concern. This analysis helps put those concerns in perspective.
The numbers in context
230 reports of suicidal events identified over 5.5 years (January 2018 to July 2023). Reporting odds ratios were calculated for the GLP-1 RA class.
How the study worked
Retrospective pharmacovigilance study using disproportionality analysis (reporting odds ratios) of the European Pharmacovigilance database from January 2018 to July 2023.
Who was studied
GLP-1 receptor agonist users in the European Pharmacovigilance database (2018-2023)
What this study cannot tell us
Spontaneous reporting databases have known limitations including underreporting, reporting bias, and inability to establish causation. The analysis can only assess reporting patterns, not true incidence.
How to read the evidence
Rated moderate: pharmacovigilance database study using established disproportionality methodology. Spontaneous reporting databases have inherent limitations.
When this study was published
Published in 2024 analyzing data through July 2023. Addresses a question raised by regulatory agencies and media reports.
The bigger picture
Millions of people take GLP-1 drugs worldwide. A confirmed suicide link would be a major safety concern. This analysis helps put the question in perspective, showing no disproportionate signal in European safety data.
Questions still open
- Could rare subgroups be at higher risk despite no class-wide signal?
- Would a prospective study with mental health endpoints provide clearer answers?
Common questions
Do GLP-1 drugs like Ozempic cause suicidal thoughts?
Should I worry about mental health on semaglutide?
Read the original research
Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.
Pharmaceuticals (Basel, Switzerland), 17(2)
Citation
Ruggiero, Rosanna; Mascolo, Annamaria; Spezzaferri, Angela; Carpentieri, Claudia; Torella, Daniele; Sportiello, Liberata; Rossi, Francesco; Paolisso, Giuseppe; Capuano, Annalisa. (2024). Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.. Pharmaceuticals (Basel, Switzerland), 17(2). https://doi.org/10.3390/ph17020147